Show simple item record

dc.contributor.authorJanssen, Michelle J M
dc.contributor.authorBruns, Anke H W
dc.contributor.authorVerduyn Lunel, Frans M
dc.contributor.authorRaijmakers, Reinier A P
dc.contributor.authorde Weijer, Roel J
dc.contributor.authorNanlohy, Nening M
dc.contributor.authorSmits, Gaby P
dc.contributor.authorvan Baarle, Debbie
dc.contributor.authorKuball, Jürgen
dc.date.accessioned2021-09-12T18:55:37Z
dc.date.available2021-09-12T18:55:37Z
dc.date.issued2021-08-20
dc.identifier.pmid34417568
dc.identifier.doi10.1038/s41409-021-01437-0
dc.identifier.urihttp://hdl.handle.net/10029/625226
dc.description.abstractVaccination after hematopoietic stem cell transplantation (HSCT) is essential to protect high-risk patients against potentially lethal infections. Though multiple studies have evaluated vaccine specific responses, no comprehensive analysis of a complete vaccination schedule post-HSCT has been performed and little is known about predictors for vaccine failure. In this context, allogeneic HSCT (alloHSCT) patients were included and vaccinated starting one year post-transplantation. Antibody responses were measured by Multiplex Immuno Assay for pneumococcal (PCV13), meningococcal C, diphtheria, pertussis, tetanus and Haemophilus influenza type b one month after the last vaccination and correlated to clinical and immunological parameters. Vaccine failure was defined as antibody response above vaccine-specific cut-off values for less than four out of six vaccines. Ninety-six patients were included of which 27.1% was found to have vaccine failure. Only 40.6% of all patients responded adequately to all six vaccines. In multivariate analysis, viral reactivation post-HSCT (OR 6.53; P = 0.03), B-cells <135 per mm3 (OR 7.24; P = 0.00) and NK-cells <170 per mm3 (OR 11.06; P = 0.00) were identified as predictors for vaccine failure for vaccination at one year post-alloHSCT. Measurement of antibody responses and an individualized approach for revaccination guided by clinical status and immune reconstitution of B-cells and NK-cells may improve vaccine responses.en_US
dc.language.isoenen_US
dc.rights© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
dc.titlePredictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients.en_US
dc.typeArticleen_US
dc.identifier.eissn1476-5365
dc.identifier.journalBone Marrow Transpl 2021; advance online publication (ahead of print)en_US
dc.source.journaltitleBone marrow transplantation
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record